)
Edge14 Aug 2026
Deutsche Qualität: The Story of Birkenstock
From an 18th-century German shoemaker to a global footwear brand, how Birkenstock turned an orthopedic insole into the world's most popular sandal.
Mesoblast
Mesoblast (MSB) investor relations material
Mesoblast Q4 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2026 earnings summary9 Jul, 2026
Executive summary
RyoncilⓇ achieved net revenue of US $36 million for the quarter and US $115 million for the full year ended June 30, 2026, surpassing initial projections.
Strong uptake of RyoncilⓇ since launch, with continued momentum expected in the coming fiscal year, especially across major U.S. pediatric centers.
RyoncilⓇ is the first FDA-approved mesenchymal stromal cell (MSC) product for any indication and the only FDA-approved therapy for children under 12 with steroid-refractory acute graft-versus-host disease (SR-aGvHD).
Financial highlights
Net revenue for the fourth quarter was US $36 million.
Full-year net revenue reached US $115 million.
Revenue growth has exceeded initial company projections.
Outlook and guidance
Continued revenue growth anticipated in the next fiscal year, supported by strong product momentum.
Operational activities are well funded through revenue growth and a new five-year facility.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Mesoblast
- Ryoncil's commercial success funds a robust pipeline targeting major inflammatory diseases.MSB
Investor presentation - Ryoncil® revenues hit US$30.3M, cash spend improved, and key clinical milestones were achieved.MSBQ3 2026
- FDA approval and new capital position the company for commercialization and growth.MSBRegistration filing
- Resale of 2,000,000 shares (200,000 ADSs) by a major shareholder, with no proceeds to the company.MSBRegistration filing
- Biotech registers 500,000 ADSs for resale; proceeds only if warrants are exercised.MSBRegistration filing
- Shareholders may resell ADSs from a recent placement as the company advances cell therapy commercialization.MSBRegistration filing
- Resale of 200,000 ADSs by a major shareholder highlights high risk and capital needs.MSBRegistration filing
- FDA approves first MSC therapy for pediatric steroid-refractory GVHD, launch imminent.MSBFDA Announcement
- RyoncilⓇ launch drove 191% revenue growth, expanded coverage, and strengthened cash reserves.MSBH2 2025
Next Mesoblast earnings date
H2 202627 Aug, 2026
Mesoblast
Next Mesoblast earnings date
H2 202627 Aug, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage